13F Pro quality score
Rank #2,583 of 2,884
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from KALA BIO, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2022 | 10-K | $3.9M | $-44.8M | — |
| FY 2021 | 10-K | $11.2M | $-142.6M | — |
| FY 2020 | 10-K | $6.4M | $-104.3M | — |
| FY 2019 | 10-K | $6.1M | $-94.3M | — |
| FY 2015 | 10-K | $45.0K | $-16.7M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
KALA BIO, Inc. (KALA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KALA at 26.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,583 of 2,884 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.1) and earnings quality (8.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of KALA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. KALA trades on the Nasdaq exchange and files with the SEC under CIK 1479419. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KALA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KALA BIO, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1479419 →